Consensus Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-19 pm EDT			5-day change	1st Jan Change
1.600 ^USD	+5.96%		+15.11%	-85.28%

Aug. 14	Ladenburg Thalmann Downgrades Marinus Pharmaceuticals to Neutral From Buy	MT
Aug. 13	Marinus Pharmaceuticals, Inc., Q2 2024 Earnings Call, Aug 13, 2024

Evolution of the Average Target: Marinus Pharmaceuticals, Inc.

Evolution of the Target Price: Marinus Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Marinus Pharmaceuticals, Inc.

78971843.x2KuH0VQDfwHhUMfB2I5fkGvhjhfh_SnrXLZDhEzog8.kxbkZg01Qs9O0xF2MhVMTiPEtV0T9LvFwxaSSyhS6UueMNcrDRNdln-8NA~0e4a721ac5415d74d65b32b2b34395e5

Analysts' recommendations: Marinus Pharmaceuticals, Inc.

Ladenburg Thalmann Downgrades Marinus Pharmaceuticals to Neutral From Buy	Aug. 14	MT
HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating	May. 07	MT
Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating	Apr. 17	MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2	Apr. 16	MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk	Apr. 16	MT
RBC Raises Price Target on Marinus Pharmaceuticals to $24 From $21, Keeps Outperform Rating	Jan. 03	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $25 From $32, Maintains Buy Rating	Nov. 08	MT
RBC Lifts Price Target on Marinus Pharmaceuticals to $21 From $20, Keeps Outperform Rating, Speculative Risk Qualifier	23-09-20	MT
Truist Securities Adjusts Price Target on Marinus Pharmaceuticals to $32 From $42, Maintains Buy Rating	23-08-11	MT
Ladenburg Thalmann Adjusts Price Target on Marinus Pharmaceuticals to $13 From $17, Maintains Buy Rating	23-08-11	MT
Oppenheimer Downgrades Marinus Pharmaceuticals to Perform From Outperform, Adjusts Price Target to $9 From $14	23-08-11	MT
Baird Adjusts Price Target on Marinus Pharmaceuticals to $20 From $24, Keeps Outperform Rating	23-08-11	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $20 From $21, Keeps Outperform Rating, Speculative Risk Qualifier	23-08-11	MT
Truist Adjusts Price Target on Marinus Pharmaceuticals to $42 From $50, Keeps Buy Rating	23-05-12	MT
RBC Lowers Price Target on Marinus Pharmaceuticals to $21 From $22, Maintains Outperform, Speculative Risk	23-05-12	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $14 From $12, Maintains Outperform Rating	23-04-25	MT
JMP Securities Adjusts Price Target on Marinus Pharmaceuticals to $18 From $19, Maintains Market Outperform Rating	23-03-08	MT
RBC Trims Price Target on Marinus Pharmaceuticals to $22 From $23, Maintains Outperform, Speculative Risk	23-03-08	MT
SVB Securities Adjusts Price Target on Marinus Pharmaceuticals to $23 From $27, Maintains Outperform Rating	23-01-23	MT
RBC Initiates Marinus Pharmaceuticals at Outperform, Speculative Risk, Sets Price Target at $23	23-01-20	MT
Baird Lowers Price Target on Marinus Pharmaceuticals to $24 From $32, Maintains Outperform Rating	22-11-09	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $12 From $23, Maintains Outperform Rating	22-11-09	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $23 From $28, Maintains Outperform Rating	22-08-12	MT
Oppenheimer Adjusts Marinus Pharmaceuticals Price Target to $28 From $32, Maintains Outperform Rating	22-05-16	MT
Cantor Fitzgerald Raises Marinus Pharmaceuticals Price Target to $28 From $25, Maintains Overweight Rating	22-04-20	MT

More recommendations

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analyst Opinion	4m Revision of opinion	Divergence of analysts' opinions	Divergence of Target Price	Ecart obj. / dr
	MARINUS PHARMACEUTICALS, INC.					+363.58%
	ELI LILLY AND COMPANY					+9.99%
	NOVO NORDISK A/S					+9.67%
	JOHNSON & JOHNSON					+3.11%
	ABBVIE INC.					+1.74%
	MERCK & CO., INC.					+17.18%
	ROCHE HOLDING AG					+12.19%
	ASTRAZENECA PLC					+17.22%
	NOVARTIS AG					+0.65%
	AMGEN INC.					-2.47%
	Average					+43.29%
	Weighted average by Cap.					+8.30%